BioRestorative up on completing patient dosing in spine disease drug trial

Biorestorative Therapies

12/06/2023 16:33

** Shares of drug developer BioRestorative Therapies Inc
 BRTX.O  up 3.6% at $5.44
    ** BRTX says last subject in its mid-stage study of BRTX-100
has been dosed
    ** Company's lead clinical candidate BRTX-100 is being
evaluated to treat chronic lumbar disc disease, a condition when
a disc in the low back area of the spine bulges out causing back
pain
    ** Initial part of the mid-stage study to evaluate safety of
BRTX-100
    ** Stock up 91% YTD

 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))